Skip to Main Content

| Download (.pdf) | Print
AAA Abdominal aortic aneurysm
ACP Association of Cancer Physicians
ADL Activities of daily living
ADT Androgen deprivation therapy
AF Atrial fibrillation
AHP Allied health professional
AML Acute myeloid leukaemia
ASA American Society of Anesthesiologists
BNP B-type natriuretic peptide
BPH Benign prostatic hypertrophy
BSC Best supportive care
CAPOX Capecitabine, oxaliplatin
CCG Clinical commissioning group
CDI Clostridium difficile infection
CGA Comprehensive Geriatric Assessment
CHOP Cyclophosphamide, doxorubicin, vincristine, prednisolone
CK Cytokeratin
CMF Cyclophosphamide, methotrexate and fluorouracil
COPD Chronic obstructive pulmonary disease
CUP Cancer of unknown primary
DCIS Ductal carcinoma in situ
DLBCL Diffuse large B cell lymphoma
DRE Digital rectal examination
EBRT External beam radiation therapy
ECOG Eastern Cooperative Oncology Group
ECX Epirubicin, cisplatin, capecitabine
eGFR Estimated glomerular filtration rate
EGFR Epidermal growth factor receptor
EORTC European Organisation for Research and Treatment of Cancer
ER Oestrogen receptor
ESMO European Society for Medical Oncology
ETF Elderly Task Force
EVAR Endoscopic repair of abdominal aortic aneurysm
FIGO International Federation of Gynecology and Obstetrics
FOLFIRI Folinic acid, fluorouracil, irinotecan
FOLFIRINOX Folinic acid, fluorouracil, irinotecan, oxaliplatin
FOLFOX Folinic acid, fluorouracil, oxaliplatin
5-FU Fluorouracil
GCSF Granulocyte colony-stimulating factor
GFR Glomerular filtration rate
GIST Gastrointestinal stromal tumour
GOJ Gastro-oesophageal junction
GTN Glyceryl trinitrate
HER2 Human epidermal growth factor receptor 2
HNA Holistic Needs Assessment
IADL Instrumental activities of daily living
IMCA Independent mental capacity advocate
LDH Lactate dehydrogenase
LMWH Low-molecular-weight heparin
LPA Lasting Power of Attorney
LVEF Left ventricular ejection fraction
MCA Mental Capacity Act 2005
MDT Multidisciplinary team
MET Metabolic equivalent of task
MIBC Muscle-invasive bladder cancer
mpMRI Multiparametric magnetic resonance imaging
mRCC Metastatic renal cell carcinoma
MUO Malignancy of unidentified primary origin
NCEI National Cancer Equality Initiative
NHSCB NHS Commissioning Board
NSAIDs Non-steroidal anti-inflammatory drugs
NSCLC Non-small-cell lung carcinoma
NTproBNP N-terminal pro-B-type natriuretic peptide
NYHA New York Heart Association
OAB Overactive bladder
OH Orthostatic hypotension
OS Overall survival
OSA Obstructive sleep apnoea
PD-1 Programmed cell death protein 1
PFS Progression-free survival
POI Pharmaceutical Oncology Initiative
PS Performance status
PSA Prostate-specific antigen
PVD Peripheral vascular disease
R-CHOP Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone
RCT Randomized controlled trial
RFA Radiofrequency ablation
R-mini-CHOP Full-dose rituximab, low-dose cyclophosphamide, doxorubicin, vincristine, prednisolone
ROC Receiver operating characteristic
SACT Systemic anticancer therapy
SIOG International Society of Geriatric Oncology
SNP Single nucleotide polymorphism
SSRI Selective serotonin reuptake inhibitor
TIA Transient ischaemic attack
TKI Tyrosine kinase inhibitor
TSH Thyroid-stimulating hormone
TTF Thyroid transcription factor
UTI Urinary tract infection
VEGF Vascular endothelial growth factor
VTE Venous thromboembolism
XELIRI Capecitabine, irinotecan

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.